Letermovir

Caitlin Soto, PharmD, BCIDP

INDICATIONS

FDA

  • Prophylaxis of cytomegalovirus infection (CMV) in adult and pediatric patients (6 months of age and older and weighing at least 6 kg) who are CMV-seropositive [R+] recipients of an allogeneic hematopoietic stem cell transplant
  • Prophylaxis of CMV in adult and pediatric patients (12 years of age and older and weighing at least 40 kg) who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: June 12, 2025